Cost-effectiveness analysis on compound anti-hypertensive tablets for primary hypertension
10.3321/j.issn:0254-6450.2008.04.017
- VernacularTitle:"降压0号"治疗原发性高血压的成本效果分析
- Author:
Yi-Qun WU
1
;
Yong-Hua HU
;
Tao REN
;
Tao WU
;
Qiu-Shan TAO
;
Xue-Ying QIN
;
Yi ZHANG
;
Si-Yan ZHAN
;
Wei-Hua CAO
;
Li-Ming LI
Author Information
1. 北京大学
- Keywords:
Hypertension;
Pharmaco economies;
Compound anti-hypertensive tablets
- From:
Chinese Journal of Epidemiology
2008;29(4):383-386
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the cost-effectiveness of two anti-hypertensive therapy regimens,Compound anti-hypertensive tablets and other common anti-hypertensive agents,in the treatment program of Primary Hypertension.Methods We conducted a cost-effectiveness analysis based on a community trial.Two communities'primary hypertensive patients were enrolled to receive different therapy drugs:Compound anti-hypertensive tablets(Group A)or other common anti-hypertensive agents(Group B).Blood pressure,medicine used,and adverse drug reactions were observed and recorded for one year,and then costeffectiveness ratio of the two groups and incremental ratio were calculated.We considered a 30%drug price fluctuating load to make the sensitivity analysis.Results 2505 cases were enrolled with 1529 cases in group A and 976 cases in group B.The cost-effectiveness ratios were 418.1 and 1057.7 for Group A and B respectively while the incremental cost-effectiveness of Group B vs.Group A was 19 202.2.The results were insensitive to variation in the costs of drugs over clinically reasonable ranges.Conclusion Compound anti-hypertensive tablets appeared to be relatively cost-effective when compared to common drugs for the treatment of primary hypertension.
